Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:VNDA
- CUSIP: 92165910
- Web: www.vandapharmaceuticals.com
Capitalization:- Market Cap: $834.36 million
- Outstanding Shares: 44,858,000
Average Prices:- 50 Day Moving Avg: $16.57
- 200 Day Moving Avg: $15.25
- 52 Week Range: $12.70 - $18.85
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -116.25
- P/E Growth: -2.86
Sales & Book Value:- Annual Revenue: $156.2 million
- Price / Sales: 5.34
- Book Value: $2.93 per share
- Price / Book: 6.35
Profitability:- EBIDTA: ($4,150,000.00)
- Net Margins: -6.54%
- Return on Equity: -7.85%
- Return on Assets: -4.90%
Debt:- Current Ratio: 2.31%
- Quick Ratio: 2.30%
Misc:- Average Volume: 536,589 shs.
- Beta: 1.47
- Short Ratio: 5.77
Frequently Asked Questions for Vanda Pharmaceuticals (NASDAQ:VNDA)
What is Vanda Pharmaceuticals' stock symbol?
Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."
How were Vanda Pharmaceuticals' earnings last quarter?
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) issued its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.21) by $0.18. The business earned $42.06 million during the quarter, compared to analysts' expectations of $40.31 million. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. The company's revenue for the quarter was up 16.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.01 EPS. View Vanda Pharmaceuticals' Earnings History.
When will Vanda Pharmaceuticals make its next earnings announcement?
Where is Vanda Pharmaceuticals' stock going? Where will Vanda Pharmaceuticals' stock price be in 2017?
7 brokers have issued 1-year price objectives for Vanda Pharmaceuticals' shares. Their forecasts range from $18.00 to $26.00. On average, they anticipate Vanda Pharmaceuticals' stock price to reach $22.14 in the next twelve months. View Analyst Ratings for Vanda Pharmaceuticals.
Who are some of Vanda Pharmaceuticals' key competitors?
Some companies that are related to Vanda Pharmaceuticals include MyoKardia (MYOK), Intercept Pharmaceuticals (ICPT), Acceleron Pharma (XLRN), Radius Health (RDUS), Lexicon Pharmaceuticals (LXRX), Clinigen Group PLC (CLIN), Sangamo Therapeutics (SGMO), Dynavax Technologies Corporation (DVAX), Ascendis Pharma A/S (ASND), Acorda Therapeutics (ACOR), Dermira (DERM), Xencor (XNCR), NeuroDerm (NDRM), Omeros Corporation (OMER), Epizyme (EPZM), Five Prime Therapeutics (FPRX), Athenex (ATNX) and Amarin Corporation PLC (AMRN).
Who are Vanda Pharmaceuticals' key executives?
Vanda Pharmaceuticals' management team includes the folowing people:
- H. Thomas Watkins, Independent Chairman of the Board
- Mihael Hristos Polymeropoulos M.D., President, Chief Executive Officer, Director
- James Patrick Kelly, Chief Financial Officer, Senior Vice President, Treasurer, Secretary
- Richard L Gulino, Senior Vice President, General Counsel, Secretary
- Gian Piero Reverberi, Senior Vice President, Acting Chief Commercial Officer and European General Manager
- Kenneth M. Bate, Director
- Michael F. Cola, Independent Director
- Richard W. Dugan, Independent Director
- Vincent J. Milano, Independent Director
Who owns Vanda Pharmaceuticals stock?
Vanda Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Palo Alto Investors LLC (9.37%), Vanguard Group Inc. (6.00%), Macquarie Group Ltd. (3.80%), State Street Corp (3.61%), FMR LLC (3.58%) and Renaissance Technologies LLC (2.46%). Company insiders that own Vanda Pharmaceuticals stock include James E Flynn, James Patrick Kelly, Mihael Hristos Polymeropoulos, Paolo Baroldi and Richard L Gulino. View Institutional Ownership Trends for Vanda Pharmaceuticals.
Who sold Vanda Pharmaceuticals stock? Who is selling Vanda Pharmaceuticals stock?
Vanda Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, TIAA CREF Investment Management LLC, Candriam Luxembourg S.C.A., Nexthera Capital LP, Wells Fargo & Company MN, Prudential Financial Inc., Columbus Circle Investors and Pacad Investment Ltd.. View Insider Buying and Selling for Vanda Pharmaceuticals.
Who bought Vanda Pharmaceuticals stock? Who is buying Vanda Pharmaceuticals stock?
Vanda Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, AJO LP, Vanguard Group Inc., Renaissance Technologies LLC, Macquarie Group Ltd., Spark Investment Management LLC, Ameriprise Financial Inc. and Numeric Investors LLC. View Insider Buying and Selling for Vanda Pharmaceuticals.
How do I buy Vanda Pharmaceuticals stock?
Shares of Vanda Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vanda Pharmaceuticals' stock price today?
One share of Vanda Pharmaceuticals stock can currently be purchased for approximately $18.60.
MarketBeat Community Rating for Vanda Pharmaceuticals (NASDAQ VNDA)MarketBeat's community ratings are surveys of what our community members think about Vanda Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Vanda Pharmaceuticals (NASDAQ:VNDA) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 7 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $22.14 (19.05% upside) |
Analysts' Ratings History for Vanda Pharmaceuticals (NASDAQ:VNDA)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/14/2017 | Oppenheimer Holdings, Inc. | Reiterated Rating | Buy | $21.00 | High |  |
| 9/14/2017 | Piper Jaffray Companies | Boost Price Target | Overweight -> Overweight | $23.00 -> $26.00 | High | |
| 8/29/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $21.00 | High | |
| 8/3/2017 | HC Wainwright | Set Price Target | Buy | $18.00 | High | |
| 4/12/2017 | CIBC | Reiterated Rating | Outperform -> Outperform | $21.00 | Low | |
| 11/9/2016 | Aegis | Initiated Coverage | Buy | $24.00 | N/A | |
| 10/10/2016 | Brean Capital | Set Price Target | Buy | $24.00 | N/A | |
| 8/26/2016 | JMP Securities | Boost Price Target | Market Outperform | $18.00 -> $22.00 | N/A | |
| 3/14/2016 | Canaccord Genuity | Reiterated Rating | Buy | $18.00 | N/A | |
(Data available from 9/24/2015 forward)
Earnings History for Vanda Pharmaceuticals (NASDAQ:VNDA)Earnings History by Quarter for Vanda Pharmaceuticals (NASDAQ VNDA)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/31/2017 | | ($0.15) | | | | | N/A | |
| 8/2/2017 | Q2 2017 | ($0.21) | ($0.03) | $40.31 million | $42.06 million | View | Listen | |
| 5/2/2017 | Q1 2017 | ($0.13) | ($0.17) | $38.35 million | $37.42 million | View | Listen | |
| 2/15/2017 | Q416 | ($0.06) | ($0.01) | $39.38 million | $38.24 million | View | Listen | |
| 11/2/2016 | Q316 | ($0.14) | ($0.01) | $38.05 million | $38.48 million | View | Listen | |
| 7/27/2016 | Q216 | ($0.23) | ($0.11) | $36.03 million | $36.02 million | View | Listen | |
| 5/4/2016 | Q116 | ($0.24) | ($0.17) | $32.48 million | $33.30 million | View | Listen | |
| 2/10/2016 | Q415 | ($0.26) | ($0.23) | $31.34 million | $31.85 million | View | Listen | |
| 11/3/2015 | Q315 | ($0.20) | ($0.11) | $28.58 million | $28.34 million | View | Listen | |
| 7/29/2015 | Q2 | ($0.32) | ($0.01) | $24.55 million | $27.60 million | View | Listen | |
| 5/6/2015 | Q1 | ($0.25) | ($0.24) | $20.18 million | $22.20 million | View | Listen | |
| 2/19/2015 | Q4 | $0.56 | ($0.36) | $35.57 million | $15.40 million | View | Listen | |
| 10/27/2014 | Q314 | ($0.39) | ($0.04) | $12.20 million | $14.80 million | View | Listen | |
| 8/7/2014 | Q2 | ($0.70) | ($0.64) | $10.00 million | $10.80 million | View | Listen | |
| 5/8/2014 | Q1 | ($0.29) | ($0.79) | $8.50 million | $9.10 million | View | Listen | |
| 2/13/2014 | Q413 | ($0.20) | ($0.23) | $8.50 million | $8.80 million | View | Listen | |
| 11/7/2013 | Q313 | ($0.30) | ($0.43) | $8.45 million | $8.70 million | View | Listen | |
| 7/31/2013 | Q2 2013 | ($0.22) | ($0.26) | $8.43 million | $8.30 million | View | Listen | |
| 5/9/2013 | Q1 2013 | ($0.25) | ($0.15) | $8.42 million | $8.10 million | View | Listen | |
| 2/12/2013 | Q4 2012 | ($0.22) | ($0.23) | $8.60 million | $7.90 million | View | Listen | |
| 11/7/2012 | Q312 | ($0.22) | ($0.19) | $8.40 million | $8.28 million | View | N/A | |
| 8/2/2012 | | ($0.27) | ($0.28) | | | View | N/A | |
| 5/8/2012 | | ($0.16) | ($0.28) | | | View | N/A | |
| 2/14/2012 | | ($0.19) | ($0.20) | | | View | N/A | |
| 11/4/2011 | | ($0.12) | ($0.11) | | | View | N/A | |
| 8/4/2011 | | ($0.07) | ($0.05) | | | View | N/A | |
| 2/10/2011 | | ($0.02) | $0.08 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)2017 EPS Consensus Estimate: ($0.65)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.18) | ($0.15) | ($0.17) |
| Q2 2017 | 2 | ($0.27) | ($0.20) | ($0.24) |
| Q3 2017 | 2 | ($0.13) | ($0.08) | ($0.11) |
| Q4 2017 | 2 | ($0.18) | ($0.10) | ($0.14) |
(Data provided by Zacks Investment Research)
Dividend History for Vanda Pharmaceuticals (NASDAQ:VNDA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Vanda Pharmaceuticals (NASDAQ:VNDA)Insider Ownership Percentage: 7.60%
Institutional Ownership Percentage: 86.49%
Insider Trades by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 1/3/2017 | Richard L Gulino | SVP | Sell | 10,900 | $15.51 | $169,059.00 | |
| 9/23/2016 | James E Flynn | Insider | Sell | 1,120,461 | $16.56 | $18,554,834.16 | |
| 9/19/2016 | James E Flynn | Insider | Sell | 547,886 | $15.66 | $8,579,894.76 | |
| 1/4/2016 | James Patrick Kelly | CFO | Sell | 9,564 | $8.96 | $85,693.44 | |
| 1/4/2016 | Mihael Hristos Polymeropoulos | CEO | Sell | 21,353 | $8.96 | $191,322.88 | |
| 1/4/2016 | Paolo Baroldi | SVP | Sell | 12,380 | $8.96 | $110,924.80 | |
| 12/11/2015 | James E Flynn | Insider | Buy | 1,201,364 | $8.38 | $10,067,430.32 | |
| 9/10/2015 | Mihael Hristos Polymeropoulos | CEO | Sell | 131,739 | $12.68 | $1,670,450.52 | |
| 5/22/2015 | Mihael Hristos Polymeropoulos | CEO | Sell | 186,395 | $10.36 | $1,931,052.20 | |
| 3/9/2015 | Richard W Dugan | Director | Sell | 4,804 | $10.69 | $51,354.76 | |
| 12/23/2014 | James E Flynn | Insider | Buy | 162,014 | $14.40 | $2,333,001.60 | |
| 3/14/2014 | Thomas Watkins | Director | Sell | 35,000 | $17.66 | $618,100.00 | |
| 11/21/2013 | Robert Repella | SVP | Sell | 107,500 | $12.03 | $1,293,225.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Vanda Pharmaceuticals (NASDAQ:VNDA)
Latest Headlines for Vanda Pharmaceuticals (NASDAQ:VNDA)
| Source: |
|
| Date | Headline |
|---|
 | $44.50 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter
www.americanbankingnews.com - September 22 at 3:22 AM |
 | These 3 Biotech Stocks Just Hit 52-Week Highs: Are They Buys?
finance.yahoo.com - September 19 at 9:22 AM |
 | Vanda Pharmaceuticals (VNDA) Presents At Morgan Stanley 15th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - September 15 at 11:05 AM |
| Is It Too Late To Buy Vanda Pharmaceuticals Inc (VNDA)?
finance.yahoo.com - September 15 at 11:05 AM |
| Vanda Pharmaceuticals Inc. (VNDA) Earns "Buy" Rating from Oppenheimer Holdings, Inc.
www.americanbankingnews.com - September 14 at 3:32 PM |
| Vanda Pharmaceuticals Inc. (VNDA) Price Target Increased to $26.00 by Analysts at Piper Jaffray Companies
www.americanbankingnews.com - September 14 at 9:08 AM |
 | Vanda Pharma shares decline as goal of itch drug study not reached - MarketWatch
www.marketwatch.com - September 13 at 9:00 PM |
| Vanda's Tradipitant Improves Itch and Disease Severity in Patients with Atopic Dermatitis
finance.yahoo.com - September 13 at 9:00 PM |
| Vanda Pharma shares decline as goal of itch drug study not reached
finance.yahoo.com - September 13 at 9:00 PM |
| Vanda Pharmaceuticals (VNDA) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 3:57 PM |
| Vanda Pharmaceuticals Announces Participation at September 2017 Investor Conferences
finance.yahoo.com - September 12 at 11:52 AM |
| Vanda Pharmaceuticals Inc. (VNDA) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - September 9 at 1:30 PM |
| Vanda Pharmaceuticals Announces Participation at the Citi 12th Annual Biotech Conference
finance.yahoo.com - September 7 at 10:56 AM |
| Jefferies Group Equities Analysts Reduce Earnings Estimates for Vanda Pharmaceuticals Inc. (VNDA)
www.americanbankingnews.com - August 31 at 8:48 AM |
| Jefferies Group Brokers Increase Earnings Estimates for Vanda Pharmaceuticals Inc. (VNDA)
www.americanbankingnews.com - August 30 at 1:48 PM |
| Vanda Pharmaceuticals Inc. (VNDA) Given Buy Rating at Jefferies Group LLC
www.americanbankingnews.com - August 29 at 1:04 PM |
| Looking for a Top Momentum Stock? 3 Reasons Why Vanda Pharmaceuticals (VNDA) is a Great Choice
finance.yahoo.com - August 29 at 9:29 AM |
| 5 Efficient Stocks to Buy for a Healthy Portfolio
finance.yahoo.com - August 25 at 12:24 PM |
| Vanda Pharmaceuticals, Inc. – Value Analysis (NASDAQ:VNDA) : August 21, 2017
finance.yahoo.com - August 23 at 1:39 PM |
| Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : August 23, 2017
finance.yahoo.com - August 23 at 1:39 PM |
| Vanda Pharmaceuticals Inc. (VNDA) Upgraded at BidaskClub
www.americanbankingnews.com - August 22 at 12:44 PM |
| Vanda Pharmaceuticals Inc. (VNDA) Expected to Announce Quarterly Sales of $44.50 Million
www.americanbankingnews.com - August 16 at 4:04 AM |
| Vanda Pharmaceuticals Inc. (VNDA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 15 at 12:16 PM |
| Vanda Pharmaceuticals Inc. (VNDA) Downgraded by BidaskClub
www.americanbankingnews.com - August 11 at 7:50 PM |
| Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : August 9, 2017
finance.yahoo.com - August 10 at 9:29 AM |
| Vanda Pharmaceuticals Inc. Expected to Earn Q3 2017 Earnings of ($0.13) Per Share (NASDAQ:VNDA)
www.americanbankingnews.com - August 7 at 7:12 AM |
| Q3 2017 EPS Estimates for Vanda Pharmaceuticals Inc. Boosted by Analyst (VNDA)
www.americanbankingnews.com - August 7 at 7:12 AM |
 | D.C. biotech is angling for massive market to treat jet lag disorders
www.bizjournals.com - August 5 at 8:16 AM |
| Vanda Pharmaceuticals preps for jet lag study results later this year - Washington Business Journal
www.bizjournals.com - August 5 at 8:16 AM |
| Vanda Pharmaceuticals preps for jet lag study results later this year
finance.yahoo.com - August 5 at 8:16 AM |
| FY2021 EPS Estimates for Vanda Pharmaceuticals Inc. Lifted by Analyst (NASDAQ:VNDA)
www.americanbankingnews.com - August 4 at 8:00 PM |
| Vanda Pharmaceuticals Inc. (VNDA) Issues Quarterly Earnings Results, Beats Estimates By $0.18 EPS
www.americanbankingnews.com - August 3 at 3:58 PM |
| Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 3 at 8:40 AM |
| Vanda Pharmaceuticals Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 3 at 8:40 AM |
| Vanda reports 2Q loss
finance.yahoo.com - August 3 at 8:40 AM |
| Edited Transcript of VNDA earnings conference call or presentation 2-Aug-17 8:30pm GMT
finance.yahoo.com - August 3 at 8:40 AM |
| Critical Comparison: Vanda Pharmaceuticals (VNDA) & bluebird bio (BLUE)
www.americanbankingnews.com - July 28 at 2:30 PM |
| Zacks: Brokerages Anticipate Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to Announce -$0.21 EPS
www.americanbankingnews.com - July 27 at 11:17 AM |
| Vanda Pharmaceuticals: An Early Stage Bioscience Consideration - Seeking Alpha
seekingalpha.com - July 27 at 9:15 AM |
| Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:58 AM |
| Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum™ for the Treatment of Schizophrenia
finance.yahoo.com - July 22 at 10:21 AM |
| Vanda Pharmaceuticals Inc. (VNDA) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - July 21 at 10:56 AM |
 | Vanda Pharmaceuticals (VNDA) Announces Negative Opinion from EMA on Fanaptum for Treatment of Schizophrenia - StreetInsider.com
www.streetinsider.com - July 21 at 8:28 AM |
 | Vanda Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 2, 2017 - PR Newswire (press release)
www.prnewswire.com - July 19 at 4:09 PM |
| Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Rating Lowered to Strong Sell at Zacks Investment Research
www.americanbankingnews.com - July 18 at 12:14 PM |
| Vanda Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 2, 2017
finance.yahoo.com - July 17 at 10:47 AM |
| Q2 2017 EPS Estimates for Vanda Pharmaceuticals Inc. (VNDA) Lowered by Analyst
www.americanbankingnews.com - July 17 at 7:06 AM |
| The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals
finance.yahoo.com - July 14 at 4:59 PM |
| $40.37 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter
www.americanbankingnews.com - July 5 at 11:47 AM |
| Zacks: Analysts Anticipate Vanda Pharmaceuticals Inc. (VNDA) to Announce -$0.23 EPS
www.americanbankingnews.com - July 3 at 10:14 AM |
Vanda Pharmaceuticals (VNDA) Chart for Sunday, September, 24, 2017
